What Is Semaglutide?
Semaglutide is a synthetic peptide—a chain of amino acids—that closely mimics the body's natural GLP-1 hormone. GLP-1 is produced in the gut and plays a critical role in regulating blood sugar levels and appetite signaling.
The compound was developed by Novo Nordisk and is marketed under two brand names depending on indication:
- Ozempic — for type 2 diabetes
- Wegovy — for chronic weight management in adults with obesity or overweight
Both contain the exact same active ingredient (semaglutide) but differ in approved dosing schedules and indications. It's administered as a once-weekly subcutaneous injection, making it convenient for most users.
How Semaglutide Works: The Mechanism
Semaglutide's effects come down to how it interacts with GLP-1 receptors—protein locks found throughout your body:
Blood Sugar Regulation
When you eat, your pancreas releases insulin to bring blood sugar down. Semaglutide enhances this response by stimulating the pancreas to release more insulin when glucose is elevated. Critically, it only triggers insulin release when blood sugar is already high—meaning hypoglycemia (dangerously low blood sugar) is rare as a standalone effect.
Appetite Suppression
GLP-1 signaling in the brain's appetite centers reduces hunger cues and increases feelings of fullness. This is why users report reduced cravings and smaller portion sizes—it's a neurological effect, not willpower.
Gastric Emptying
Semaglutide slows the rate at which food moves from your stomach into your intestines. This prolongs satiety (fullness) and helps stabilize blood sugar spikes after meals.
Clinical Evidence: What 584 Trials Tell Us
Semaglutide has an exceptionally robust evidence base. Here's what the landmark data shows:
Type 2 Diabetes
The SUSTAIN trial series demonstrated that semaglutide reduced HbA1c (average 3-month blood sugar) by 1.0–1.8 percentage points compared to placebo, with some trials showing superiority to other diabetes drugs. Across multiple studies, approximately 50–60% of users achieved HbA1c targets below 7% (the clinical goal for most diabetics).
Weight Loss
The STEP trial series (for Wegovy) is where semaglutide gained mainstream attention:
- STEP 1: Users on 2.4 mg semaglutide lost an average of 10.2 kg (22.5 lbs) over 68 weeks, compared to 2.6 kg for placebo—a net difference of ~7.6 kg.
- STEP 2: In patients with type 2 diabetes, semaglutide users lost 6.5 kg vs. 1.0 kg for placebo.
- STEP 3: Combined with lifestyle counseling, the 2.4 mg dose achieved 15.3% body weight reduction.
These aren't modest numbers. For context, bariatric surgery typically achieves 20–35% weight loss, so semaglutide approaches surgical outcomes without surgery.
Cardiovascular Outcomes
The SUSTAIN-6 trial showed that semaglutide reduced major adverse cardiovascular events (heart attacks, strokes, cardiovascular death) by 26% in people with type 2 diabetes and established heart disease—a finding that influenced its approval for cardiovascular risk reduction.
Regulatory Status & Approvals
Semaglutide holds regulatory approval in three major markets:
United States (FDA)
FDA approved Ozempic in December 2017 for type 2 diabetes. Wegovy received FDA approval in June 2021 for chronic weight management in adults with obesity or overweight. The FDA has since expanded indications and approved higher dosing schedules.
Europe (EMA)
The EMA authorised Ozempic in September 2018 and Wegovy in November 2021. EMA approval followed similar clinical evidence standards and predicated on demonstrated safety and efficacy.
Canada (Health Canada)
Health Canada approved both indications, allowing semaglutide access to Canadian patients through provincial coverage programs (though accessibility varies by province).
The breadth of these approvals reflects the regulatory confidence in the compound's benefit-risk profile.
Safety Profile & Side Effects
Semaglutide is generally well-tolerated, but it comes with known side effects and contraindications worth understanding.
Common Side Effects
The most frequently reported adverse events in clinical trials were gastrointestinal:
- Nausea (25–50% of users, usually transient)
- Vomiting (5–10%)
- Diarrhea (10–20%)
- Constipation (15–25%)
Importantly, these effects typically diminish after 4–8 weeks as the body adapts. Users are advised to start at a low dose and escalate gradually—a strategy called "titration" that minimizes GI upset.
Serious Safety Considerations
Pancreatitis Risk: Post-marketing surveillance has identified rare cases of acute pancreatitis. The causal link remains debated, but semaglutide is contraindicated in patients with a personal or strong family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2).
Dehydration: GI side effects and reduced appetite can lead to inadequate fluid intake. Users are advised to maintain hydration.
Hypoglycemia: In type 2 diabetes patients already on insulin or sulfonylureas, semaglutide increases hypoglycemia risk, so dose adjustments to other medications may be necessary.
Gallbladder Issues: Rapid weight loss (from any cause) increases gallstone formation risk. This is inherent to weight loss, not unique to semaglutide.
Pregnancy: Semaglutide is not recommended during pregnancy. Users of childbearing age should use contraception and discontinue before attempting conception.
Discontinuation Effects
When users stop semaglutide, weight typically regains and blood sugar control deteriorates over weeks to months. Clinical trials show that sustained weight loss requires ongoing use—it's not a "one-time fix."
Who Benefits Most?
Ideal Candidates for Diabetes Use
- Type 2 diabetes patients with inadequate glycemic control on other drugs
- Those with established cardiovascular disease (semaglutide reduces CV events)
- Overweight/obese diabetics (weight loss is a bonus)
Ideal Candidates for Weight Management
- Adults with BMI ≥27 (or BMI ≥30) and weight-related health conditions
- Those with documented weight loss resistance to diet and exercise alone
- Patients motivated to inject once weekly
Comparison to Similar Compounds
Semaglutide isn't alone in the GLP-1 space. Related compounds include:
- Tirzepatide — a dual GIP/GLP-1 agonist showing slightly higher weight loss (up to 22% in trials)
- Liraglutide — an earlier GLP-1 agonist requiring daily injections; semaglutide's weekly dosing is more convenient
- Dulaglutide — another weekly GLP-1 agonist with similar efficacy but different pharmacokinetics
Among GLP-1 agonists, semaglutide remains the gold standard for both efficacy and convenience.
The Cost & Access Question
Semaglutide is expensive. A month's supply (typically 4 injections) costs $900–$1,500 USD without insurance. Insurance coverage varies:
- Medicare: Generally covers Ozempic for type 2 diabetes; Wegovy coverage is limited
- Private insurance: Many cover Ozempic; Wegovy coverage depends on the plan
- Uninsured patients: Novo Nordisk offers assistance programs and patient savings cards
Cost remains the primary barrier to access, though this is evolving as generic and biosimilar versions develop.
Key Takeaways
- Evidence-based: 584 clinical trials provide robust safety and efficacy data across diabetes and weight management
- Regulatory gold standard: Approved by FDA, EMA, and Health Canada
- Dual benefit: Manages blood sugar and weight in type 2 diabetes
- Convenience: Once-weekly injection
- Real limitations: GI side effects, cost, ongoing use required for sustained results
Semaglutide represents a meaningful advance in metabolic medicine, but it's a tool—not a magic solution. Success requires medical oversight, realistic expectations, and often behavioral change.
Glossary
Unfamiliar terms? See our guides to GLP-1 receptor agonists and subcutaneous injection.